Table 2 Levels of biomarkers
(A) PAT study group | ME/CFS | PCS | HC | p value* | |||
|---|---|---|---|---|---|---|---|
Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | ||
Serum ET-1 (pg/ml) | 1.434 (1.208–1.622) | 14 | 1.168 (1.019–1.328) | 16 | 1.141 (1.014–1.302) | 15 | p1 = 0.0804 p2 = 0.0221 p3 > 0.9999 |
Serum Esm-1 (ng/ml) | 2.013 (1.199–4.890) | 14 | 2.013 (1.366–6.223) | 16 | 1.782 (0.984–3.399) | 15 | p1 > 0.9999 p2 > 0.9999 p3 > 0.9999 |
Serum Ang-2 (pg/ml) | 1866 (1502–2108) | 14 | 1621 (1283–1762) | 16 | 2058 (1566–3459) | 15 | p1 = 0.9341 p2 = 0.4715 p3 = 0.0379 |
Serum ACE (U/l) | 25.20 (17.70–32.35) | 14 | 27.50 (23.65–32.65) | 16 | Normal range**: 20–70 | p1 = 0.4043 | |
Serum ACE2 (U/ml) | 5.099 (4.192–6.162) | 14 | 4.476 (3.946–6.476) | 16 | 4.971 (4.23–6.792) | 15 | p1 > 0.9999 p2 > 0.9999 p3 = 0.5715 |
IL-8 post-erythrocyte lysis (pg/ml) | 139.9 (116.7–197.6) | 14 | 188.2 (150.2–217.0) | 16 | Normal range**:  < 150 | p1 = 0.0592 | |
 > 150 | 7 |  > 150 | 12 | ||||
(B) Validation study group | ME/CFS | PCS | HC | PCHC | p value* | ||||
|---|---|---|---|---|---|---|---|---|---|
Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Â | |
Serum ET-1 (pg/ml) | 1.110 (0.980–1.325) | 25 | 1.130 (0.750–1.310) | 25 | 0.820 (0.770–0.940) | 47 | 0.830 (0.723–0.948) | 20 | p1 > 0.9999 p2 = 0.0003 p3 = 0.0384 p4 = 0.0007 p5 = 0.0365 p6 > 0.9999 |
Serum Ang-2 (pg/ml) | 2759 (2193–3425) | 26 | 2149 (1564–2535) | 30 | 2977 (2355–4143) | 50 | 2356 (1802–3027) | 20 | p1 = 0.0188 p2 > 0.9999 p3 < 0.0001 p4 = 0.5336 p5 > 0.9999 p6 = 0.0234 |
Serum ACE (U/l) | 29.20 (20.10–42.20) | 23 | 23.70 (19.43–31.75) | 30 | Normal range**: 20–70 | NA | p1 = 0.1643 | ||
IL-8 post-erythrocyte lysis (pg/ml) | 172.6 (136.9–198.0) | 25 | 150.2 (126.7–180.1) | 29 | Normal range**:  < 150 | NA | p1 = 0.0884 | ||
 > 150 | 17 |  > 150 | 15 | ||||||